‘Ozempic Baby Boom’: How GLP-1 Agonists Affect Fertility

Weight-loss drugs like Ozempic are helping some women get pregnant by accident, but doctors still don’t know if the drugs are safe once a baby is on the way.

Quick Take

Doctors say GLP-1 drugs like Ozempic and Wegovy can restore ovulation in women with obesity or PCOS, leading to surprise pregnancies nicknamed “Ozempic babies.”
The drugs may also slow how the stomach absorbs birth control pills, which could make some oral contraceptives less reliable.
Major reviews say human pregnancy safety data remain limited, and drugmakers left pregnant women out of clinical trials.
Regulators tell patients to stop the drugs about two months before trying to conceive, but no study has proven a nationwide baby boom is actually happening.

How Weight-Loss Drugs Can Trigger Surprise Pregnancies

GLP-1 drugs, including Ozempic and Wegovy, treat diabetes and obesity. Doctors now say the same drugs can boost fertility in women with obesity or polycystic ovary syndrome, known as PCOS. Losing weight improves how the body handles insulin, which often restores ovulation. Medical reviews report higher pregnancy rates in women who lost significant weight on these drugs.

A University of Michigan fertility expert said women who lost 15 to 20 percent of their body weight on these drugs sometimes started ovulating again after years of irregular cycles. Many did not expect to get pregnant so quickly. Doctors are now watching this pattern closely, since it links two well-known medical facts: obesity often blocks fertility, and dramatic weight loss can help fix that.

Birth Control Pills May Not Work As Expected

Some doctors warn that GLP-1 drugs can slow down digestion, which may affect how birth control pills get absorbed. Nausea and vomiting, common side effects when starting these drugs or raising the dose, can also stop a pill from working the way it should. One drug safety report tied to the medicine tirzepatide found oral contraceptive levels dropped by about 20 percent after a single dose.

Because of this risk, some manufacturers now recommend backup birth control methods, like condoms, during the first month of treatment or after a dose increase. Doctors say patients on these drugs who also take the pill should talk to their doctor about switching methods or adding extra protection during that window.

Pregnancy Safety Data Remain Thin

Despite the fertility benefits, doctors do not know if GLP-1 drugs are safe for a growing baby. Drug companies Novo Nordisk and Eli Lilly left pregnant women out of their clinical trials, so most safety information comes from smaller observational studies after the fact. One study found higher rates of preterm birth and low blood sugar in newborns exposed to semaglutide, though it did not find more birth defects.

Other studies paint a more reassuring picture. A 2026 review of pregnancy outcomes found no consistent rise in major birth defects or serious problems after early exposure, though researchers called the evidence “low quality” because the study groups were small. One Danish study included just 32 pregnancies exposed to semaglutide, far too few to rule out rare risks.

Why Doctors Still Urge Caution Before Conceiving

Current guidance tells patients to stop GLP-1 drugs about two months before trying to get pregnant, since the medicine can stay in the body for weeks. A spokesperson for Novo Nordisk told reporters there simply is not enough data yet to know the real risk of birth defects or miscarriage, and that animal testing showed some potential danger to a developing fetus.

No study has actually measured a nationwide jump in births tied to these drugs. What exists is a mix of doctor observations, small pregnancy registries, and mechanistic theories about weight loss and digestion. That gap between a catchy headline and hard population data is worth remembering as more people take these drugs and more of these stories surface.

The bigger story here isn’t hype or fear — it’s a familiar pattern. A new drug hits the market fast, real medical benefits show up quickly, but the safety research needed to protect families lags years behind. Patients are left making high-stakes decisions with incomplete information, while regulators and drug companies play catch-up.